Boswellia / AKBA

Boswellia extract/AKBA inhibits 5-LOX/NF-κB/STAT3, induces apoptosis, reduces tumor growth/metastasis; human signals for edema reduction and anti-proliferation in cancer.

← All agents

Human-reviewed · How we review →

AI extractedhuman reviewedsources checkedretractions suppressed

👥⭐⭐ Low to Moderate — Strong mechanistic and in vivo data; early human signals (breast window trial, brain-tumor edema) but limited cancer-outcome trials.FrankincenseBoswellia serrata extractIndian frankincenseSalai guggal

Forms: Boswellia extract capsules (300–500 mg, standardized to 30–60% boswellic acids)

Educational only, not medical advice. OncoForge makes no claim that Boswellia / AKBA treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.

Simple Summary

AKBA turns down leukotriene/NF-κB inflammation, switches on apoptosis, and lowers invasion/angiogenesis genes. Human signals include less brain-tumor edema and reduced tumor proliferation in a breast ‘window’ trial; direct survival benefits remain unproven.

Evidence at a glance

Tier 2 · animalBreastBrain (Glioblastoma)PancreaticVarious (preclinical)

Low to Moderate — Strong preclinical; human trials show edema reduction and anti-proliferation, but limited outcome data.

How it may work

Acetyl-11-keto-β-boswellic acid (AKBA) directly inhibits 5-lipoxygenase, lowering leukotrienes and inflammation; suppresses NF-κB–regulated survival, proliferation, and angiogenic genes; inhibits STAT3 signaling; and induces caspase-dependent apoptosis. In vivo, AKBA reduces tumor growth and metastasis in a pancreatic cancer model with downregulation of VEGF, COX-2, MMP-9, and CXCR4. AKBA can reach the brain in animals, boswellic acids show activity against glioblastoma cells, and Boswellia extracts have reduced cerebral edema in brain-tumor patients and decreased proliferation in a breast cancer window trial.

Targets & pathways

Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.

5-Lipoxygenase (5-LOX)↓Reduces leukotrienes and inflammation
NF-κB↓Suppresses survival, proliferation, angiogenic genes
STAT3↓
Apoptosis↑Caspase-dependent
Tumor Growth / Metastasis↓Downregulates VEGF, COX-2, MMP-9, CXCR4
Cerebral Edema↓In brain tumor patients

5-LOXNF-κBApoptosis

Often studied / combined with

Combinations reported in the literature, not a protocol or a recommendation.

Curcumin: Enhanced anti-inflammatory/apoptosis.
Radiation: Reduces edema/dermatitis.
Chemotherapy: Potential sensitization.

Overlapping mechanisms

NF-κB ↓: Avoid stacking with other strong NF-κB inhibitors without monitoring.

Safety & interactions

Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.

Risk categories

Gi Upset MildAllergic ReactionsBleeding RiskPregnancy Avoid

Potential interactions

Anticoagulants / Antiplatelets (e.g., warfarin, aspirin)MonitorModerateTheoreticalPotential increased bleeding risk.
P-gp substrates (e.g., certain chemotherapies)MonitorMinorTheoreticalMay affect drug transport.
Radiation / ChemotherapyConsiderBeneficialTheoreticalMay reduce edema and enhance effects; preclinical synergies.

Timing

With meals: To improve absorption and reduce GI upset.
Divided doses: 2–3 times daily for steady levels.

References

Research

No published studies for Boswellia / AKBA yet

New studies appear here once they’ve been reviewed. Browse all studies.

Dose: as studied, not a recommendation

These are doses as studied or reported, never a recommendation. The right amount of Boswellia / AKBA depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.

Ranges seen in adjunct / practice use: 2400–4500 mg (po) Divided into 2–3 doses daily. Based on human trials: 2400 mg/day in breast cancer window trial; 4200 mg/day in brain tumor edema RCT; 3600–4500 mg/day reported in radiation necrosis studies., No Rx required. Use standardized extracts (e.g., to AKBA/boswellic acids); take with food. Oncology adjunct—consult clinician; monitor for GI effects..

Trials studying Boswellia / AKBA

No actively-recruiting trials matched right now. Recruiting is not the same as proven. Search ClinicalTrials.gov →

Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.

← All agents · Research Radar